Unique ID issued by UMIN | UMIN000058066 |
---|---|
Receipt number | R000066323 |
Scientific Title | A Study on Plasma Markers for Early Detection of Pancreatic Cancer |
Date of disclosure of the study information | 2025/06/30 |
Last modified on | 2025/06/03 12:58:00 |
A Study on Plasma Markers for Early Detection of Pancreatic Cancer
A Study on Plasma Markers for Early Detection of Pancreatic Cancer
A Study on Plasma Markers for Early Detection of Pancreatic Cancer
A Study on Plasma Markers for Early Detection of Pancreatic Cancer
Japan |
Pancreatic Cancer
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery | Radiology |
Malignancy
NO
This study aims to investigate the usefulness of plasma SPINK1 levels for the early detection of pancreatic cancer and to calculate the sensitivity and specificity of plasma SPINK1 concentration with an appropriate threshold value.
Bio-availability
The utility of plasma SPINK1 concentration in predicting the presence of pancreatic cancer
1. The sensitivity and specificity of plasma SPINK1 levels for predicting pancreatic cancer, along with an appropriate threshold setting
2. The association between Plasma SPINK1 levels and patient background factors (age, gender, BMI)
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
2
Prevention
Other |
Blood collection: Approximately 2 ml of blood is collected in healthy control case.
Blood collection: Approximately 2 ml of blood is collected in pancreatic cancer case.
40 | years-old | <= |
85 | years-old | >= |
Male and Female
Healthy Control Cases
Cases that meet all of the following criteria:
- Age between 40 and 85 years inclusive
- Written informed consent obtained from the individual for participation in this study
Pancreatic Cancer Cases
Cases that meet all of the following criteria:
- Age between 40 and 85 years inclusive
- Written informed consent obtained from the individual for participation in this study
- Registered in the separate trial titled "Investigation of Hypoxic Regions and the Effectiveness of Radiotherapy in Pancreatic Cancer (C1491-1)"
Cases that meet any of the following criteria will be excluded from this study:
- History of malignant tumors
- Cases deemed inappropriate by the principal investigator or co-investigators due to medical or other factors (e.g., poor general condition)
60
1st name | Hiroshi |
Middle name | |
Last name | Harada |
Kyoto University
Radiation Biology Center, Graduate School of Biostudies
606-8501
Yoshida Konoe-cho, Sakyo-ku, Kyoto City, Kyoto, Japan
075-753-7560
harada.hiroshi.5e@kyoto-u.ac.jp
1st name | Tatsuya |
Middle name | |
Last name | Suwa |
Kyoto University Hospital
Department of Radiation Oncology and Image-applied Therapy
606-8507
54 Shogoin Kawara-cho, Sakyo-ku, Kyoto City, Kyoto, Japan
075-751-3762
tsuwa@kuhp.kyoto-u.ac.jp
Kyoto University
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Kyoto University Graduate School and Faculty of Medicine, Ethics Committee
53 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, Japan
075-366-7618
ethcom@kuhp.kyoto-u.ac.jp
NO
2025 | Year | 06 | Month | 30 | Day |
Unpublished
Open public recruiting
2022 | Year | 07 | Month | 04 | Day |
2022 | Year | 07 | Month | 04 | Day |
2022 | Year | 07 | Month | 04 | Day |
2028 | Year | 06 | Month | 30 | Day |
2025 | Year | 06 | Month | 03 | Day |
2025 | Year | 06 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066323